Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193127 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
A Phase 2 study, sponsored by Omeros Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 223
- Enrollment target
NCT01193127 is a Phase 2 study that has completed, run by Omeros Corporation. The registered enrollment target is 223 participants.
The verdict
NCT01193127, a Phase 2 study, has completed, sponsored by Omeros Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 223 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintaining an adequately dilated pupil during surgery and reducing post-operative symptoms of discomfort (such as eye pain and irritation).
Interventions
- DRUG OMS302 Solution
- DRUG OMS302 Mydriatic Solution
- DRUG OMS302 Anti-inflammatory Solution
- DRUG Balanced Salt Solution (BSS) Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193127
The ClinicalTrials.gov registry entry for NCT01193127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which OMS302 Solution is the first listed.
NCT01193127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01193127 about?
NCT01193127 is a clinical study titled "Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)". The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintaining an adequately dilated pupil during surgery and reducing post-operative symptoms of discomfort (...
What is the current status of trial NCT01193127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2010-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01193127?
The interventions under investigation include: OMS302 Solution (DRUG), OMS302 Mydriatic Solution (DRUG), OMS302 Anti-inflammatory Solution (DRUG), Balanced Salt Solution (BSS) Solution (DRUG).
Who is sponsoring clinical trial NCT01193127?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.